Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

1,028

Participants

Timeline

Start Date

October 21, 2021

Primary Completion Date

April 4, 2022

Study Completion Date

April 4, 2022

Conditions
RSV
Interventions
BIOLOGICAL

RSVpreF (Group 1)

RSV vaccine (RSVpreF)

BIOLOGICAL

RSVpreF (Group 2)

RSV vaccine (RSVpreF)

BIOLOGICAL

RSVpreF (Group 3)

RSV vaccine (RSVpreF)

BIOLOGICAL

Placebo

Placebo

Trial Locations (18)

28401

Accellacare - Wilmington, Wilmington

30281

Clinical Research Atlanta, Stockbridge

32789

Clinical Site Partners, Inc, Winter Park

Clinical Site Partners, Winter Park

33016

Global Health Research Center, Inc., Miami Lakes

33351

Precision Clinical Research, Sunrise

40004

Kentucky Pediatric/ Adult Research, Bardstown

43213

Aventiv Research Inc, Columbus

63141

Sundance Clinical Research, St Louis

68134

Meridian Clinical Research, LLC, Omaha

77081

Texas Center for Drug Development, Inc., Houston

77375

DM Clinical Research, Tomball

78705

Benchmark Research, Austin

83404

Clinical Research Prime, Idaho Falls

84109

J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City

84121

J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City

96814

East-West Medical Research Institute, Honolulu

02818

Velocity Clinical Research, Providence, East Greenwich

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05096208 - Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age | Biotech Hunter | Biotech Hunter